Deciphering Early and Progressive Molecular Signatures in Alzheimer's Disease through Integrated Longitudinal Proteomic and Pathway Analysis in a Rodent Model

Alzheimer's disease (AD), the leading cause of dementia worldwide, remains a challenge due to its complex origin and degenerative character. The need for accurate biomarkers and treatment targets hinders early identification and intervention. To fill this gap, we used a novel longitudinal prote...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of molecular sciences Vol. 25; no. 12; p. 6469
Main Authors:	Yadikar, Hamad, Ansari, Mubeen A, Abu-Farha, Mohamed, Joseph, Shibu, Thomas, Betty T, Al-Mulla, Fahd
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 01-06-2024 MDPI
Subjects:	Advertising executives Alzheimer Disease - genetics Alzheimer Disease - metabolism Alzheimer Disease - pathology Alzheimer's disease Alzheimer’s disease proteomics Animals Biomarkers Biomarkers - metabolism Brain research Data mining Disease Disease Models, Animal Disease Progression Diseases Glucose Huntingtons disease Hypotheses Insulin resistance intracerebroventricular streptozotocin Kuwait Machine learning Male Metabolism Mice neurodegenerative biomarkers Pathogenesis Pathology pathway dysregulation Peptides Pharmacogenetics Protein expression Proteins Proteome - metabolism Proteomics - methods Scientific equipment and supplies industry Signal Transduction Target marketing temporal expression profiling United States Kuwait United States Alzheimer’s disease proteomics pathway dysregulation intracerebroventricular streptozotocin neurodegenerative biomarkers temporal expression profiling
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Alzheimer's disease (AD), the leading cause of dementia worldwide, remains a challenge due to its complex origin and degenerative character. The need for accurate biomarkers and treatment targets hinders early identification and intervention. To fill this gap, we used a novel longitudinal proteome methodology to examine the temporal development of molecular alterations in the cortex of an intracerebroventricular streptozotocin (ICV-STZ)-induced AD mouse model for disease initiation and progression at one, three-, and six-weeks post-treatment. Week 1 revealed metabolic protein downregulation, such as Aldoa and Pgk1. Week 3 showed increased Synapsin-1, and week 6 showed cytoskeletal protein alterations like Vimentin. The biological pathways, upstream regulators, and functional effects of proteome alterations were dissected using advanced bioinformatics methods, including Ingenuity Pathway Analysis (IPA) and machine learning algorithms. We identified Mitochondrial Dysfunction, Synaptic Vesicle Pathway, and Neuroinflammation Signaling as disease-causing pathways. Huntington's Disease Signaling and Synaptogenesis Signaling were stimulated while Glutamate Receptor and Calcium Signaling were repressed. IPA also found molecular connections between PPARGC1B and AGT, which are involved in myelination and possible neoplastic processes, and MTOR and AR, which imply mechanistic involvements beyond neurodegeneration. These results help us comprehend AD's molecular foundation and demonstrate the promise of focused proteomic techniques to uncover new biomarkers and therapeutic targets for AD, enabling personalized medicine.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1422-0067 1661-6596 1422-0067
DOI:	10.3390/ijms25126469